Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Richard MELSHEIMER"'
Autor:
Aniela Bonorino Xexeo Castelo BRANCO, Wilton ARGOLO, Nathalia SANTOS, Gabriela HERNANDEZ, Adriana KAKEHASI, Carlos Walter SOBRADO, Richard MELSHEIMER
Publikováno v:
Arquivos de Gastroenterologia, Vol 61 (2024)
ABSTRACT Background: Monoclonal antibodies have proven efficacy in the management of several conditions and infliximab (IFX) is one of the most important drugs of the class. Some recent data have shown low rates of both persistence and adherence to s
Externí odkaz:
https://doaj.org/article/4ef1ec9af615432891d3c9f0588c6113
Autor:
Iris Lin, Richard Melsheimer, Rachel H. Bhak, Patrick Lefebvre, Maral DerSarkissian, Bruno Emond, Angela Lax, Catherine Nguyen, Melody Wu, Yinong Young-Xu
Publikováno v:
Current Medical Research and Opinion. 38:613-627
To compare treatment patterns of United States (US) veterans stable on innovator infliximab (IFX) who switched to an IFX biosimilar (switchers) or remained on innovator IFX (continuers).US Veterans Healthcare Administration data (01/2012-12/2019) wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c065342921e193b9afb3b211cbabe66
https://doi.org/10.1080/03007995.2022.2037846
https://doi.org/10.1080/03007995.2022.2037846
Autor:
Yinong Young-Xu, Richard Melsheimer, Bruno Emond, Patrick Lefebvre, Maral DerSarkissian, Angela Lax, Catherine Nguyen, Rachel H. Bhak, Melody Wu, Iris Lin
Publikováno v:
Current medical research and opinion. 38(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa8f34b7d2d2695553cc8baf52188554
https://pubmed.ncbi.nlm.nih.gov/36274636
https://pubmed.ncbi.nlm.nih.gov/36274636
Autor:
Jane, O'Halloran, Eyal, Kedar, Kevin J, Anstrom, Matthew W, McCarthy, Emily R, Ko, Patricia, Segura Nunez, Cynthia, Boucher, P Brian, Smith, Reynold A, Panettieri, Sabina, Mendivil Tuchia de Tai, Martin, Maillo, Akram, Khan, Alfredo J, Mena Lora, Matthias, Salathe, Gerardo, Capo, Daniel, Rodriguez Gonzalez, Thomas F, Patterson, Christopher, Palma, Horacio, Ariza, Maria, Patelli Lima, Anne M, Lachiewicz, John, Blamoun, Esteban, Nannini, Eduardo, Sprinz, Analia, Mykietiuk, Radica, Alicic, Adriana M, Rauseo, Cameron R, Wolfe, Britta, Wittig, Daniel K, Benjamin, Steven E, McNulty, Pearl, Zakroysky, Susan, Halabi, Sandra, Butler, Jane, Atkinson, Stacey J, Adam, Richard, Melsheimer, Soju, Chang, Lisa, LaVange, Michael, Proschan, Samuel A, Bozzette, William G, Powderly
Publikováno v:
medRxiv
BackgroundImmune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care.MethodsWe conducted a mast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c636f160d614202fc158d1f4336836d
https://pubmed.ncbi.nlm.nih.gov/36172138
https://pubmed.ncbi.nlm.nih.gov/36172138
The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
Publikováno v:
Advances in Therapy
In the USA, an interchangeability designation provides biosimilar sponsors with a pathway for achieving what is standard for small-molecule generics: pharmacy-level auto-substitution for an innovator. No other major health authority links interchange
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d86cd9d7abaedf21e8507ca87178908d
https://doi.org/10.1007/s12325-021-01688-9
https://doi.org/10.1007/s12325-021-01688-9
Autor:
Timothy Fitzgerald, Patrick Lefebvre, Laura Morrison, I. Lin, Richard Melsheimer, Bruno Emond, Marie-Hélène Lafeuille, Kimberly Woodruff
Publikováno v:
Biologics : Targets & Therapy
Timothy Fitzgerald,1 Richard Melsheimer,2 Marie-Hélène Lafeuille,3 Patrick Lefebvre,3 Laura Morrison,3 Kimberly Woodruff,1 Iris Lin,1 Bruno Emond3 1Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA; 2Medical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::666a639c6c2a07f3fcc04d1d88430aec
http://europepmc.org/articles/PMC7797299
http://europepmc.org/articles/PMC7797299
Publikováno v:
Biologics: Targets and Therapy. 13:139-178
On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn's disease. Subsequently, Remicade was approve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ac8282d070a5a1eb1fc830cca24a956
https://doi.org/10.2147/btt.s207246
https://doi.org/10.2147/btt.s207246
Autor:
Colleen Marano, Freddy Cornillie, Paul Rutgeerts, J Omoniyi Adedokun, Jean-Frederic Colombel, George Philip, Richard Melsheimer
Publikováno v:
Journal of Crohn's and Colitis. 13:1257-1264
Background and Aims In nonresponders to golimumab induction for ulcerative colitis, we assessed clinical response rates and golimumab serum concentrations when the 100-mg dose was used early in the course of maintenance. Methods This post-hoc analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a0dc7cda1ccc58227881fea3656853b
https://doi.org/10.1093/ecco-jcc/jjz052
https://doi.org/10.1093/ecco-jcc/jjz052
Autor:
Kavitha Goyal, Donald Neblock, Melissa Calmann, Frank Van Gog, Albert DeRitis, Vinod Philip, Lawrence Doolittle, Richard Melsheimer
Publikováno v:
Biodrugs
Biologics are produced from living organisms in complex, multi-stage manufacturing processes and contain inherent variability, which must be understood and controlled during manufacturing to avoid unexpected changes in key quality attributes that may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b1f703390c3a072fec5eb4b6aa565a7
https://doi.org/10.1007/s40259-018-0300-7
https://doi.org/10.1007/s40259-018-0300-7
Publikováno v:
Zeitschrift für Gastroenterologie. 56:e220-e221
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d220b2e1af689425116d4acea000d469
https://doi.org/10.1055/s-0038-1668704
https://doi.org/10.1055/s-0038-1668704